Literature DB >> 34511196

Inherited Pancreatic Cancer Syndromes and High-Risk Screening.

Leah H Biller1, Brian M Wolpin2, Michael Goggins3.   

Abstract

Pancreatic cancer is the third leading cause of cancer death in the United States, with a 5-year survival rate of 9%. Individuals with inherited pancreatic cancer syndromes are at an increased risk for developing pancreatic cancer and may benefit from pancreatic cancer surveillance with the goal to detect and intervene on early-stage cancer or high-risk precursor lesions. Given the screening implications for family members and therapeutic implications for probands, all patients diagnosed with pancreatic cancer are recommended to undergo germline genetic testing.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer risk; Hereditary; Pancreatic cyst; Surveillance

Mesh:

Year:  2021        PMID: 34511196      PMCID: PMC8438225          DOI: 10.1016/j.soc.2021.06.002

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   2.402


  76 in total

Review 1.  Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas.

Authors:  Masao Tanaka; Carlos Fernández-Del Castillo; Terumi Kamisawa; Jin Young Jang; Philippe Levy; Takao Ohtsuka; Roberto Salvia; Yasuhiro Shimizu; Minoru Tada; Christopher L Wolfgang
Journal:  Pancreatology       Date:  2017-07-13       Impact factor: 3.996

2.  Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.

Authors:  Phuong L Mai; Ana F Best; June A Peters; Rosamma M DeCastro; Payal P Khincha; Jennifer T Loud; Renée C Bremer; Philip S Rosenberg; Sharon A Savage
Journal:  Cancer       Date:  2016-08-06       Impact factor: 6.860

3.  Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma.

Authors:  Spring Holter; Ayelet Borgida; Anna Dodd; Robert Grant; Kara Semotiuk; David Hedley; Neesha Dhani; Steven Narod; Mohammad Akbari; Malcolm Moore; Steven Gallinger
Journal:  J Clin Oncol       Date:  2015-05-04       Impact factor: 44.544

4.  Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden).

Authors:  H F Vasen; N A Gruis; R R Frants; P A van Der Velden; E T Hille; W Bergman
Journal:  Int J Cancer       Date:  2000-09-15       Impact factor: 7.396

5.  Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms.

Authors:  Maeve A Lowery; Winston Wong; Emmet J Jordan; Jonathan W Lee; Yelena Kemel; Joseph Vijai; Diana Mandelker; Ahmet Zehir; Marinela Capanu; Erin Salo-Mullen; Angela G Arnold; Kenneth H Yu; Anna M Varghese; David P Kelsen; Robin Brenner; Erica Kaufmann; Vignesh Ravichandran; Semanti Mukherjee; Michael F Berger; David M Hyman; David S Klimstra; Ghassan K Abou-Alfa; Catherine Tjan; Christina Covington; Hannah Maynard; Peter J Allen; Gokce Askan; Steven D Leach; Christine A Iacobuzio-Donahue; Mark E Robson; Kenneth Offit; Zsofia K Stadler; Eileen M O'Reilly
Journal:  J Natl Cancer Inst       Date:  2018-10-01       Impact factor: 13.506

6.  Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling.

Authors:  Robert R McWilliams; Eric D Wieben; Kari G Rabe; Katrina S Pedersen; Yanhong Wu; Hugues Sicotte; Gloria M Petersen
Journal:  Eur J Hum Genet       Date:  2010-12-08       Impact factor: 4.246

7.  Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers.

Authors:  Hans Vasen; Isaura Ibrahim; Carmen Guillen Ponce; Emily P Slater; Elvira Matthäi; Alfredo Carrato; Julie Earl; Kristin Robbers; Anneke M van Mil; Thomas Potjer; Bert A Bonsing; Wouter H de Vos Tot Nederveen Cappel; Wilma Bergman; Martin Wasser; Hans Morreau; Günter Klöppel; Christoph Schicker; Martin Steinkamp; Jens Figiel; Irene Esposito; Evelina Mocci; Enrique Vazquez-Sequeiros; Alfonso Sanjuanbenito; Maria Muñoz-Beltran; José Montans; Peter Langer; Volker Fendrich; Detlef K Bartsch
Journal:  J Clin Oncol       Date:  2016-04-25       Impact factor: 44.544

8.  Mortality and cancer incidence in 263 patients with ataxia-telangiectasia.

Authors:  D Morrell; E Cromartie; M Swift
Journal:  J Natl Cancer Inst       Date:  1986-07       Impact factor: 13.506

9.  BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study.

Authors:  David B Zhen; Kari G Rabe; Steven Gallinger; Sapna Syngal; Ann G Schwartz; Michael G Goggins; Ralph H Hruban; Michele L Cote; Robert R McWilliams; Nicholas J Roberts; Lisa A Cannon-Albright; Donghui Li; Kelsey Moyes; Richard J Wenstrup; Anne-Renee Hartman; Daniela Seminara; Alison P Klein; Gloria M Petersen
Journal:  Genet Med       Date:  2014-11-20       Impact factor: 8.822

10.  Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer.

Authors:  Brian M Wolpin; Cosmeri Rizzato; Peter Kraft; Charles Kooperberg; Gloria M Petersen; Zhaoming Wang; Alan A Arslan; Laura Beane-Freeman; Paige M Bracci; Julie Buring; Federico Canzian; Eric J Duell; Steven Gallinger; Graham G Giles; Gary E Goodman; Phyllis J Goodman; Eric J Jacobs; Aruna Kamineni; Alison P Klein; Laurence N Kolonel; Matthew H Kulke; Donghui Li; Núria Malats; Sara H Olson; Harvey A Risch; Howard D Sesso; Kala Visvanathan; Emily White; Wei Zheng; Christian C Abnet; Demetrius Albanes; Gabriella Andreotti; Melissa A Austin; Richard Barfield; Daniela Basso; Sonja I Berndt; Marie-Christine Boutron-Ruault; Michelle Brotzman; Markus W Büchler; H Bas Bueno-de-Mesquita; Peter Bugert; Laurie Burdette; Daniele Campa; Neil E Caporaso; Gabriele Capurso; Charles Chung; Michelle Cotterchio; Eithne Costello; Joanne Elena; Niccola Funel; J Michael Gaziano; Nathalia A Giese; Edward L Giovannucci; Michael Goggins; Megan J Gorman; Myron Gross; Christopher A Haiman; Manal Hassan; Kathy J Helzlsouer; Brian E Henderson; Elizabeth A Holly; Nan Hu; David J Hunter; Federico Innocenti; Mazda Jenab; Rudolf Kaaks; Timothy J Key; Kay-Tee Khaw; Eric A Klein; Manolis Kogevinas; Vittorio Krogh; Juozas Kupcinskas; Robert C Kurtz; Andrea LaCroix; Maria T Landi; Stefano Landi; Loic Le Marchand; Andrea Mambrini; Satu Mannisto; Roger L Milne; Yusuke Nakamura; Ann L Oberg; Kouros Owzar; Alpa V Patel; Petra H M Peeters; Ulrike Peters; Raffaele Pezzilli; Ada Piepoli; Miquel Porta; Francisco X Real; Elio Riboli; Nathaniel Rothman; Aldo Scarpa; Xiao-Ou Shu; Debra T Silverman; Pavel Soucek; Malin Sund; Renata Talar-Wojnarowska; Philip R Taylor; George E Theodoropoulos; Mark Thornquist; Anne Tjønneland; Geoffrey S Tobias; Dimitrios Trichopoulos; Pavel Vodicka; Jean Wactawski-Wende; Nicolas Wentzensen; Chen Wu; Herbert Yu; Kai Yu; Anne Zeleniuch-Jacquotte; Robert Hoover; Patricia Hartge; Charles Fuchs; Stephen J Chanock; Rachael S Stolzenberg-Solomon; Laufey T Amundadottir
Journal:  Nat Genet       Date:  2014-08-03       Impact factor: 41.307

View more
  3 in total

Review 1.  The Emerging Role of EVA1A in Different Types of Cancers.

Authors:  Huijie Zhao; Huiyang Liu; Yihan Yang; Honggang Wang
Journal:  Int J Mol Sci       Date:  2022-06-15       Impact factor: 6.208

2.  Clinical Study of Anti-PD-1 Immunotherapy Combined with Gemcitabine Chemotherapy in Multiline Treatment of Advanced Pancreatic Cancer.

Authors:  Yanfeng Liu; Yanchuan Li; Shan Du; Li Fan; Junyan Wang
Journal:  Comput Math Methods Med       Date:  2022-09-06       Impact factor: 2.809

Review 3.  Targeting PI3K/AKT/mTOR Signaling Pathway in Pancreatic Cancer: From Molecular to Clinical Aspects.

Authors:  Silviu Stanciu; Florentina Ionita-Radu; Constantin Stefani; Daniela Miricescu; Iulia-Ioana Stanescu-Spinu; Maria Greabu; Alexandra Ripszky Totan; Mariana Jinga
Journal:  Int J Mol Sci       Date:  2022-09-04       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.